Advanz Expands Challenge To Rival's Bowel Disease Drug IP
Pharmaceutical company Advanz has expanded its challenge to a rival's protections over the bowel disease drug Entyvio, asking a London court to revoke three additional patents besides the one it had...To view the full article, register now.
Already a subscriber? Click here to view full article